Recent approvals have established the viability of
antibody-drug conjugates, and open the door to future
products that are more efficacious, better tolerated
and applicable to broader patient populations.
Donald Bergstrom, Timothy Lowinger and Peter Park, Mersana Therapeutics (June 2014)
Keywords: Antibody-drug conjugates,
DNA damaging agents,
Potent drug payloads